418 results
6-K
EX-99.3
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated
6-K
EX-99.2
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine
6-K
EX-99.4
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated
6-K
EX-99.1
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
in such incorporated documents shall be deemed to be modified or superseded for the purpose of this prospectus to the extent that a subsequent statement … of the holders of that series of debt securities voting together with the holders of other of our debt securities as a single class for this purpose
F-3ASR
EX-1.1
zf4gj29638s2
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
F-3ASR
EX-25.1
dib76b5db7
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
F-3ASR
EX-4.1
bukjt59zv
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
S-8
3jae1ay h2oqh3k4
4 Apr 24
Registration of securities for employees
8:45am
S-8
EX-5.1
ba377m s3q
4 Apr 24
Registration of securities for employees
8:45am
S-8
406we1f nttvdo
4 Apr 24
Registration of securities for employees
8:45am
6-K
EX-99.1
rthn5 vdpbg7yqhja
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
6-K
EX-99.4
odq 25ikzm6
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
ez9qnh 9sb242
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.2
vsamjdkoua8 zv
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.3
umkz2cx lpf
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.5
aktlw37
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
ugy2n8ti
15 Feb 24
Current report (foreign)
12:09pm
6-K
EX-99.1
o1gpc lpp6dsk97
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.2
fvy7rw ov
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm